LIST OF FIGURES

Figure No.	TITLE	Page No.
Figure 1.1	Multiple protein sequence alignment of ubiquitin protein sequences.	5
Figure 1.2	Ubiquitin encoding genes in S. cerevisiae and mouse.	8
Figure 1.3	Cartoon structure of ubiquitin.	9
Figure 1.4	Ubiquitin lysine linkages along with facilitated functions.	13
Figure 1.5	Forms of ubiquitination.	14
Figure 1.6	3D structure of ubiquitin activating enzyme E1.	16
Figure 1.7	Structure of ubiquitin conjugating enzyme E2	18
Figure 1.8	Mechanism of HECT E3s and domains involved in various HECT families.	20
Figure 1.9	Ubiquitin transfer mechanism of RING E3s accompanied by monomeric, homodimeric and heteromeric RING and U-box RING E3s. Multi-subunit RING E3s, APC and Cullin-RING E3 ligase are also shown.	21
Figure 1.10	Ubiquitin transfer mechanism of RIR (RING-IBR-RING) domain E3s. Proteins containing RIR domain are also displayed.	22
Figure 1.11	3D structure of 26S proteasome showing catalytic particle (CP) and regulatory particle (RP) subunits.	25
Figure 1.12	The enzymatic reaction of ubiquitin proteasome pathway.	27
Figure 1.13	Drugs targeting ubiquitin proteasome pathway.	33
Figure 2.1	Cartoon structure of UbWt and UbEP42 showing original and substituted amino acid residues.	41
Figure 2.2	Effect of overexpression of ubiquitin variants on SUB60 cells.	42
Figure 2.3	Ubiquitin variants affect growth pattern of SUB60 cells.	42
Figure 2.4	Effect of expression of mutations on the survival of SUB60 cells upon exposure to heat stress.	43
Figure 2.5	Vector map of pUG46.	49
Figure 2.6	Vector map of pUB221.	51
Figure 2.7	The vector map of pUB23.	53
Figure 2.8	Confocal images showing influence of ubiquitin variants on budding and cell cycle.	55
Figure 2.9	Consequence of ubiquitin mutants on cell cycle progression.	56
Figure 2.10	BrdU cell proliferation assay.	57
Figure 2.11	Western blot showing the levels of Cdc28 protein kinase and Fus3 MAPK in SUB60 cells and its transformants expressing UbWt, UbEP42 and single mutants of ubiquitin.	58
Figure 2.12	Monitoring mRNA levels of CDC28 protein kinase and FUS3 MAPK.	59
Figure 2.13	Protein levels of Cdc28 and Fus3 in presence and absence of proteasome inhibitor.	60
Figure 2.14	Monitoring mRNA levels of CDC37 and CLN3. ACT1 used as	61

	internal control.	
Figure 2.15	Levels of reactive oxygen species in presence of mutant ubiquitin in SUB60 cells	62
Figure 2.16	Effect of mutant forms of ubiquitin on lysosomal degradation of uracil permease.	63
Figure 2.17	1% agarose gel showing clone confirmation of GFP tagged carboxypeptidase S.	64
Figure 2.18	Effect of expression of UbWt, UbEP42, UbS20F, UbA46S, UbL50P and UbI61T on the sorting of carboxypeptidase S (CPS) monitored using confocal microscopy.	65
Figure 2.19	Antibiotic stress complementation of Saccharomyces cerevisiae (SUB60).	68
Figure 2.20	Confirmation of clone construction in pUb221 vector with RE digestions.	70
Figure 2.21	Polyubiquitination profile of mutant forms of ubiquitin expressing SUB60 cells.	71
Figure 2.22	Western blot analysis showing K63 and K48 linked polyubiquitnation profile in ubiquitin wild type and mutants expressing SUB60 cells.	72
Figure 2.23	The N-end rule pathway showing primary, secondary and tertiary destabilizing residues and their components.	73
Figure 2.24	Effect of UbWt, UbEP42 and its single mutant derivatives on the half-life of proteins in SUB60 cells.	75
Figure 2.25	Representative image showing cumulative effects of mutant forms of ubiquitin.	82
Figure 3.	1 Secondary structural features of ubiquitin along with position of four mutations viz. S20F, A46S, L50P and I61T.	82
Figure 3.2	UbF45W, synthetic yeast ubiquitin gene containing restriction sites.	84
Figure 3.3	Map of pKK223-3 bacterial expression vector.	85
Figure 3.4	15% DNA-PAGE showing fragments of mutagenic amplicon of ubiquitin.	88
Figure 3.5	Restriction enzyme digestion pattern of yeast ubiquitin wild type as well as variant ubiquitin amplicons.	89
Figure 3.6	Confirmation of cloning of ubiquitin mutations by insert release.	90
Figure 3.7	15% SDS-PAGE showing the overexpression of ubiquitin variants.	91
Figure 3.8	15% SDS-PAGE showing presence of ubiquitin protein after heat treatment.	91
Figure 3.9	15% SDS-PAGE showing purified ubiquitin proteins.	92
Figure 3.10	Far UV circular dichroism spectra of mutants and wild type ubiquitin protein.	93
Figure 3.11	Near UV circular dichroism spectra of mutants and wild type ubiquitin protein.	95
Figure 3.12	Far-UV circular dichroism spectra of UbEP42, UbL50P and UbI61T in presence of 20% and 40% TFE.	96
Figure 3.13	Fluorescence emission spectra of UbEP42, UbS20F, UbA46S,	97

	UbL50P and UbI61T in comparison with UbF45W recorded by exciting the protein at 280nm.	
Figure 3.14	Changes in λmax of intrinsic fluorescence emission of UbF45W and the ubiquitin mutants UbEP42, UbS20F, UbA46S, UbL50P and UbI61T as a function of guanidine hydrochloride concentration.	98
Figure 4.1	(A) life cycle of C. albicans (B) morphogenesis in C. albicans from yeast to pseudohyphae and hyphae.	104
Figure 4.2	Pictorial representation of key virulence factors of C. albicans.	105
Figure 4.3	Effect of overexpression of UbEP42 and its single mutant derivatives on *C. albicans*.	110
Figure 4.4	Influence of ubiquitin protein mutants on growth profile and viability of *C. albicans* cells.	112
Figure 4.5	The effect of expression of ubiquitin mutants on cell cycle progression.	113
Figure 4.6	Effect of ubiquitin variants on the survival of C. albicans cells subjected to heat stress and thermotolerence test.	115
Figure 4.7	Effects of mutant ubiquitin protein on the survival of *C. albicans* under antibiotic stress.	116
Figure 4.8	Western blot analysis showing polyubiquitination profile of K63 and K48 linkages of *C. albicans* cells expressing mutant forms of ubiquitin.	117
Figure 4.9	Initiation and maintenance of hyphal development in *C. albicans* CAI4 cells and their transformants.	118
Figure 5.1	Synthetic human ubiquitin gene.	127
Figure 5.2	Strategy of cloning mutant forms and wild type ubiquitin encoding gene in mammalian expression vector.	128
Figure 5.3	Vector maps of pTRE-Tight-IRES EGFP and pTet-On.	128
Figure 5.4	(A) and (B) shows vector maps of pTRE-Tight and pTet-On respectively which are used for inducing mutant ubiquitin protein in MCF-7 cells. The modulatory mechanism of Tet-On system in presence of doxycycline (Dox) is shown in (C).	130
Figure 5.5	Strategy for generating chimeric EGFP tagged mutant ubiquitin.	134
Figure 5.6	Gel picture showing the amplified fragments of ubiquitin using mutagenic and non-mutagenic primers to generate mutant ubiquitin genes. Amplicon size and lane labelling are given in the Table next to gel image.	135
Figure 5.7	DNA-PAGE (15%) showing PCR amplicon of ubiquitin gene.	135
Figure 5.8	Agarose gel showing RE confirmation of ubiquitin mutant genes.	137
Figure 5.9	Overexpression of EGFP under Tet promoter.	138
Figure 5.10	Consequences of mutant as well as wild type ubiquitin proteins on MCF-7 cells.	139
Figure 5.11	Influence of high level expression of HUbWt and mutant forms of ubiquitin on the growth rate of MCF-7 cells.	140
Figure 5.12	Implications of variants of ubiquitin HUbEP42 and its single mutant derivatives on clonigenic ability of MCF-7 cells.	142
Figure 5.13	Stress response of HUbEP42 and its single mutant expressing MCF-7 cells upon antibiotics exposure.	143

Figure 5.14	Agarose gel image showing RE mapping of pTRE-Tight vector harbouring HUbWt and other ubiquitin variants.	144
Figure 5.15	Microscopic evidence of mutant ubiquitin protein localization in MCF-7 cells.	146

LIST OF TABLES

Sr. No.	TITLE	Page No.
Table 1.1	Prokaryotic protein homologues of ubiquitin and ubiquitin activating enzyme E1.	3
Table 1.2	Diseases associated with ubiquitin proteasome pathway.	31
Table 2.1	Oligonucleotide sequence of genes to study mRNA transcript level.	44
Table 3.1	List of mutagenic and non-mutagenic primers used for generating mutant forms of ubiquitin.	83
Table 3.2	Secondary structural analysis of far UV CD spectra of the wild type and mutant forms of ubiquitin using CD Pro software.	93
Table 3.3	Structural preferences of original and substituting residues for β-turns as observed by Hutchinson and Thornton, 1994 and for β-sheets by Chou and Fasman, 1978 are also indicated (Doshi et.al., 2014).	98
Table 5.1	List of forward (FR) and reverse (RE) oligonucleotide used to generate single mutant derivatives of mammalian ubiquitin by site directed mutagenesis.	125